

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM822805

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	TRADEMARK SECURITY AGREEMENT		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
MYRIAD GENETICS, INC.		06/30/2023	Corporation: DELAWARE
MYRIAD WOMEN'S HEALTH, INC.		06/30/2023	Corporation: DELAWARE
GATEWAY GENOMICS, LLC		06/30/2023	Limited Liability Company: DELAWARE
ASSUREX HEALTH, INC.		06/30/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	JPMORGAN CHASE BANK, N.A.		
<b>Street Address:</b>	4 CHASE METROTECH CENTER		
<b>City:</b>	BROOKLYN		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	11245-0001		
<b>Entity Type:</b>	National Banking Association: UNITED STATES		
<b>PROPERTY NUMBERS Total: 42</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4639345	ASSUREX	
<b>Registration Number:</b>	2209514	BRACANALYSIS	
<b>Registration Number:</b>	4832846	BRACANALYSIS CDX	
<b>Registration Number:</b>	5135495	CHANGING LIVES THROUGH GENETIC INSIGHT	
<b>Registration Number:</b>	2602350	COLARIS	
<b>Registration Number:</b>	2818115	COLARIS AP	
<b>Registration Number:</b>	5232053	COUNSYL	
<b>Registration Number:</b>	5000031	CPGX	
<b>Registration Number:</b>	5611618	DNA & DONUTS	
<b>Registration Number:</b>	5558369	FORESIGHT	
<b>Registration Number:</b>	4332579	GENESIGHT	
<b>Registration Number:</b>	4742168		
<b>Registration Number:</b>	6981371	HEALTH. ILLUMINATED.	
<b>Registration Number:</b>	4890008	M-CO	
<b>Registration Number:</b>	4909150	MYCHOICE	

CH \$1065.00 4639345

Property Type	Number	Word Mark
Registration Number:	1920379	MYRIAD
Registration Number:	6919741	MYRIAD GENETICS
Registration Number:	4960566	MYRIAD MYCHOICE
Registration Number:	4860135	MYRIAD MYRISK
Registration Number:	4658522	MYRIADPRO
Registration Number:	6939366	MYRISK
Registration Number:	4323671	MYSUPPORT360
Registration Number:	4744265	MYVISION
Registration Number:	4486168	PHENO
Registration Number:	5174212	PRECISION MEDICINE FOR PERSONAL WELLNESS
Registration Number:	6403958	PREQUEL
Registration Number:	3909371	PROLARIS
Registration Number:	5371453	RISKSCORE
Registration Number:	4827955	SNEAKPEEK
Registration Number:	6363350	SNEAKPEEK EARLY GENDER DNA TEST
Registration Number:	6659653	SNEAKPEEK SNAP
Registration Number:	6364393	SNEAKPEEK TRAITS
Registration Number:	1906102	
Registration Number:	5135494	
Serial Number:	90522805	AMPLIFY
Serial Number:	97217881	FIRSTGENE
Serial Number:	97720320	FIRSTGENE
Serial Number:	97682394	MYGENEHISTORY
Serial Number:	90660096	MYRIAD GENETICS
Serial Number:	90696908	PRECISE
Serial Number:	90522813	PREQUEL WITH AMPLIFY
Serial Number:	97655950	UROSUITE

**CORRESPONDENCE DATA**

Fax Number: 2124552502

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 2124552592

Email: ksolomon@stblaw.com

Correspondent Name: COURTNEY WELSHIMER, ESQ.

Address Line 1: SIMPSON THACHER & BARTLETT LLP

Address Line 2: 425 LEXINGTON AVENUE

Address Line 4: NEW YORK, NEW YORK 10017

ATTORNEY DOCKET NUMBER: 509265/2454

<b>NAME OF SUBMITTER:</b>	COURTNEY WELSHIMER
<b>SIGNATURE:</b>	/CW/
<b>DATE SIGNED:</b>	07/07/2023
<b>Total Attachments: 7</b> source=Myriad - Trademark Security Agreement - Executed_Rev#page1.tif source=Myriad - Trademark Security Agreement - Executed_Rev#page2.tif source=Myriad - Trademark Security Agreement - Executed_Rev#page3.tif source=Myriad - Trademark Security Agreement - Executed_Rev#page4.tif source=Myriad - Trademark Security Agreement - Executed_Rev#page5.tif source=Myriad - Trademark Security Agreement - Executed_Rev#page6.tif source=Myriad - Trademark Security Agreement - Executed_Rev#page7.tif	

TRADEMARK SECURITY AGREEMENT dated as of June 30, 2023 (this “Agreement”), between MYRIAD GENETICS, INC., MYRIAD WOMEN’S HEALTH, INC., GATEWAY GENOMICS, LLC, and ASSUREX HEALTH, INC. (the “Grantors”) and JPMORGAN CHASE BANK, N.A., as Administrative Agent for the Secured Parties (the “Administrative Agent”).

Reference is made to (a) that certain Credit Agreement dated as of June 30, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), the other Loan Parties party thereto, the Lenders and Issuing Banks from time to time party thereto and the Administrative Agent, and (b) that certain Pledge and Security Agreement dated as of June 30, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Borrower, the other Grantors from time to time party thereto and the Administrative Agent. The Lenders and the Issuing Banks have extended, and have agreed to extend, credit to the Borrower subject to the terms and conditions set forth in the Credit Agreement. The Grantors (other than the Borrower) are Affiliates of the Borrower, will derive substantial benefits from the extension of credit to the Borrower under the Credit Agreement and are willing to execute and deliver this Agreement in order to induce the Lenders and the Issuing Banks to extend such credit. Accordingly, the parties hereto agree as follows:

SECTION 1. Terms. Each capitalized term used but not otherwise defined herein shall have the meaning specified in the Credit Agreement or the Security Agreement, as applicable. The rules of construction specified in Section 1.03 of the Credit Agreement also apply to this Agreement, *mutatis mutandis*.

SECTION 2. Grant of Security Interest. To secure the prompt and complete payment or performance of the Secured Obligations, each Grantor hereby pledges, assigns and grants to the Administrative Agent, on behalf of and for the ratable benefit of the Secured Parties, a security interest in all of such Grantor’s right, title and interest in, to and under the portion of the Collateral constituting United States Trademarks (including those Trademark registrations and applications listed on Schedule I hereto), whether now owned by or owing to, or hereafter acquired by or arising in favor of such Grantor (collectively, the “Trademark Collateral”); provided, however, that the Trademark Collateral shall not include any Excluded Property.

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The security interest granted hereby has been granted to the Administrative Agent for the benefit of the Lenders in connection with the Security Agreement and is expressly subject to the terms and conditions thereof and shall terminate in accordance with Section 8.14 thereof. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Administrative Agent with respect to the Trademark Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.


SECTION 4. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, and all of which, when taken together, shall constitute one agreement. Subject to the terms of the Credit Agreement, delivery of an executed counterpart of a signature page of this Agreement that is an Electronic Signature (as defined in the Credit Agreement) transmitted by facsimile, emailed .pdf or any other electronic means that reproduces an image of the actual executed signature page shall be effective as delivery of a manually executed counterpart of this Agreement.

SECTION 5. CHOICE OF LAW. THIS AGREEMENT A SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK, BUT GIVING EFFECT TO FEDERAL LAWS APPLICABLE TO NATIONAL BANKS.

*[Signature Pages Follow.]*

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

MYRIAD GENETICS, INC.

By:   
Name: R. Bryan Riggsbee  
Title: Chief Financial Officer


MYRIAD WOMEN'S HEALTH, INC.

By:   
Name: R. Bryan Riggsbee  
Title: Chief Financial Officer

ASSUREX HEALTH, INC.

By:   
Name: R. Bryan Riggsbee  
Title: Chief Financial Officer


GATEWAY GENOMICS, LLC

By:   
Name: R. Bryan Riggsbee  
Title: Chief Financial Officer

---

*[Signature Page to Trademark Security Agreement]*

JPMORGAN CHASE BANK, N.A.,  
as Administrative Agent

By:   
Name: Melanie Her  
Title: Vice President

**SCHEDULE I**

Trademark Registrations and Applications

<b>Title</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Reg. No.</b>	<b>Reg. Date</b>	<b>Record Owner</b>
ASSUREX	85/928,926	5/10/2013	4,639,345	11/18/2014	Assurex Health, Inc.
BRACANALYSIS	75/172,876	9/27/1996	2,209,514	12/8/1998	Myriad Genetics, Inc.
BRACANALYSIS CDX	86/278,932	5/12/2014	4,832,846	10/13/2015	Myriad Genetics, Inc.
CHANGING LIVES THROUGH GENETIC INSIGHT	86/839,257	12/4/2015	5,135,495	2/7/2017	Assurex Health, Inc.
COLARIS	76/128,845	9/14/2000	2,602,350	7/30/2002	Myriad Genetics, Inc.
COLARIS AP	76/408,353	5/15/2002	2,818,115	2/24/2004	Myriad Genetics, Inc.
COUNSYL	87/236,426	11/14/2016	5,232,053	6/27/2017	Myriad Women's Health, Inc.
CPGX	86/730,912	8/20/2015	5,000,031	7/12/2016	Assurex Health, Inc.
DNA & DONUTS	87/871,451	4/10/2018	5,611,618	11/20/2018	Gateway Genomics, LLC
FORESIGHT	87/330,185	2/9/2017	5,558,369	9/11/2018	Myriad Women's Health, Inc.
GENESIGHT	85/460,254	10/31/2011	4,332,579	5/7/2013	Assurex Health, Inc.
GENESIGHT COLOR LOGO	86/275,609	5/8/2014	4,742,168	5/26/2015	Assurex Health, Inc.
HEALTH. ILLUMINATED.	90/602,703	3/25/2021	6,981,371	2/14/2023	Myriad Genetics, Inc.
M-CO	86/152,794	12/26/2013	4,890,008	1/19/2016	Myriad Genetics, Inc.
MYCHOICE	85/924,750	5/6/2013	4,909,150	3/1/2016	Myriad Genetics, Inc.
MYRIAD	74/476,513	1/4/1994	1,920,379	9/19/1995	Myriad Genetics, Inc.
MYRIAD GENETICS (Non-Stacked)	90/978,386	4/21/2021	6,919,741	12/6/2022	Myriad Genetics, Inc.
MYRIAD MYCHOICE	85/924,749	5/6/2013	4,960,566	5/17/2016	Myriad Genetics, Inc.
MYRIAD MYRISK	85/924,742	5/6/2013	4,860,135	11/24/2015	Myriad Genetics, Inc.
MYRIADPRO	86/116,473	11/12/2013	4,658,522	12/23/2014	Myriad Genetics, Inc.



Title	Serial No.	Filing Date	Reg. No.	Reg. Date	Record Owner
MYRISK	97/028,783	9/15/2021	6,939,366	1/3/2023	Myriad Genetics, Inc.
MYSUPPORT360	85/703,382	8/14/2012	4,323,671	4/23/2013	Myriad Genetics, Inc.
MYVISION (DESIGN)	86/009,082	7/12/2013	4,744,265	5/26/2015	Myriad Genetics, Inc.
PHENO	85/785,621	11/21/2012	4,486,168	2/18/2014	Myriad Genetics, Inc.
PRECISION MEDICINE FOR PERSONAL WELLNESS	86/839,247	12/4/2015	5,174,212	4/4/2017	Assurex Health, Inc.
PREQUEL	88/190,978	11/12/2018	6,403,958	6/29/2021	Myriad Genetics, Inc.
PROLARIS	78/825,099	2/28/2006	3,909,371	1/18/2011	Myriad Genetics, Inc.
RISKSCORE	87/271,930	12/16/2016	5,371,453	1/2/2018	Myriad Genetics, Inc.
SNEAKPEEK	86/237,720	3/31/2014	4,827,955	10/6/2015	Gateway Genomics, LLC
SNEAKPEEK EARLY GENDER DNA TEST	90/192,687	9/18/2020	6,363,350	5/25/2021	Gateway Genomics LLC
SNEAKPEEK SNAP	90/793,371	6/24/2021	6,659,653	3/1/2022	Gateway Genomics LLC
SNEAKPEEK TRAITS	90/274,962	10/23/2020	6,364,393	5/25/2021	Gateway Genomics LLC
STYLIZED HELIX LOGO	74/476,182	1/4/1994	1,906,102	7/18/1995	Myriad Genetics, Inc.
X Design	86/839,230	12/4/2015	5,135,494	2/7/2017	Assurex Health, Inc.
AMPLIFY	90/522,805	2/10/2021			Myriad Genetics, Inc.
FIRSTGENE	97/217,881 <sup>1</sup>	1/13/2022			Myriad Genetics, Inc.
FIRSTGENE	97/720,320 <sup>2</sup>	12/16/2022			Myriad Genetics, Inc.
MYGENEHISTORY	97/682,394	11/17/2022			Myriad Genetics, Inc.
MYRIAD GENETICS (Stacked)	90/660,096 <sup>3</sup>	4/21/2021			Myriad Genetics, Inc.

<sup>1</sup> This is an intent-to-use trademark application and is not included in the Trademark Collateral until a statement of use or amendment to allege use is filed and accepted by the United States Patent and Trademark Office.

<sup>2</sup> This is an intent-to-use trademark application and is not included in the Trademark Collateral until a statement of use or amendment to allege use is filed and accepted by the United States Patent and Trademark Office.

<sup>3</sup> This is an intent-to-use trademark application and is not included in the Trademark Collateral until a statement of

Title	Serial No.	Filing Date	Reg. No.	Reg. Date	Record Owner
PRECISE	90/696,908 <sup>4</sup>	5/7/2021			Myriad Genetics, Inc.
PREQUEL WITH AMPLIFY	90/522,813	2/10/2021			Myriad Genetics, Inc.
UROSUITE	97/655,950 <sup>5</sup>	10/31/2022			Myriad Genetics, Inc.

---

use or amendment to allege use is filed and accepted by the United States Patent and Trademark Office. Statement of Use filed with USPTO on June 27, 2023.

<sup>4</sup> This is an intent-to-use trademark application and is not included in the Trademark Collateral until a statement of use or amendment to allege use is filed and accepted by the United States Patent and Trademark Office.

<sup>5</sup> This is an intent-to-use trademark application and is not included in the Trademark Collateral until a statement of use or amendment to allege use is filed and accepted by the United States Patent and Trademark Office.